Systematic review / meta-analysis / 2024
Higher soy isoflavone intake was linked to a lower risk of coronary heart disease and overall cardiovascular disease in adults.
Researchers evaluated the link between soy isoflavone intake and cardiovascular outcomes across prospective cohort studies published up to September 2021. High intake was significantly associated with a lower risk of CHD overall (pooled RR: 0.92, 95% CI: 0.85-0.99) and lower risks of CVD (pooled RR: 0.91, 95% CI: 0.84-0.98) and CHD (pooled RR: 0.89, 95% CI: 0.83-0.96) in Western populations. Linear dose-response analysis showed each 3 mg/day increase was associated with a 16% lower risk of CVD and 14% lower risk of CHD in Western populations.
Shows an association, not proof of cause and effect.
- Study type
- Systematic review and dose-response meta-analysis
- Who was studied
- Adults from prospective cohort studies (13 publications reviewed, 12 in meta-analysis)
- What was measured
- Risk of cardiovascular disease (CVD) and coronary heart disease (CHD)
THE PAPER
Soy isoflavone intake and risk of cardiovascular disease in adults: A systematic review and dose-response meta-analysis of prospective cohort studies.
Naghshi S, Tutunchi H, Yousefi M, Naeini F, Mobarak S, Asadi M, Sadeghi O. Crit Rev Food Sci Nutr, 2024.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.